New UC research identifies biological differences in pancreatic cancer
Findings published in Cancer Research could help personalize pancreatic cancer treatment
New research from the University of Cincinnati Cancer Center found biological differences in pancreatic cancer tumors and immune environments, opening the possibility for more personalized treatments for different populations.
Nina Steele, PhD. Photo/University of Cincinnati.
Led by Nina Steele, PhD, assistant professor in UC’s College of Medicine, in collaboration with Howard Crawford, PhD, scientific director of the Henry Ford + Michigan State University Pancreatic Cancer Center, the research was recently published in the journal Cancer Research.
Incidence and survival rates of pancreatic cancer vary between different populations of Americans, but sufficient data did not previously exist to determine specific genomic differences between populations.
“We didn’t have an accurate reflection of all of the patients impacted by the disease reflected in the data,” said Steele, who is also a Cancer Center member. “There had never been a large-scale multiomic effort looking at tens of thousands of biological markers across a diverse cohort of pancreatic cancer patients.”
Steele and her colleagues at Henry Ford Health (where she started the project) and UC mapped out the genomic information of a representative sample of the American population diagnosed with pancreatic cancer.
Pancreatic cancer is 20% more likely to develop in Black African Americans (BAA), and the team found the cancer cells of BAA and Non-African Americans (NAA) had different molecular signatures.
“The cancer cells make unique RNAs and proteins, so that could be relevant to how individual patients from different groups could respond to targeted therapies like RAS inhibitors,” Steele said. “The markers upregulated in Black patients likely represent a type of cells typically associated with drug resistance, so this biological difference could play a role in outcomes.”
We’re headed toward forecasting, the ability to better predict what will happen to every patient in their journey before it happens.
Nina Steele, PhD
Additionally, a type of immune cell called B cells within pancreatic tumor microenvironments are different between BAA and NAA populations, with the B cells within BAA samples found to be more abundant but also more immunosuppressive (dampening the body’s natural immune response to fight the cancer).
“This may mean the B cells are helping the cancer cells hide in this patient population,” Steele said. “This could help explain why this population is more likely to get the cancer, and why it’s worse when they get it, but more work is needed on pancreas tissues from individuals that do not have cancer.”
Steele said the study provides a framework for further research into the mechanisms behind these biological differences across populations and how the differences affect outcomes.
The research is part of a larger trend of personalized medicine, with more detailed data leading to specific treatments to meet the individual needs of patients. Further research could even potentially lead to the classification of entirely new subtypes of pancreatic cancer, similar to what has occurred in breast and prostate cancer.
“The Cancer Center is here to serve everybody, and to find the answers that help all patients,” Steele said. “The hope is to know more about the characteristics of the cancer cells earlier on, so that we have a plan of attack for what therapies come after current standards of care in a very rational way. We’re headed toward forecasting, the ability to better predict what will happen to every patient in their journey before it happens.”
The next groundbreaking discovery
UC is a powerhouse of discovery and impact as a Carnegie 1 research institution. From pioneering medical research to transformative engineering and social innovation, our faculty and students drive progress that reaches across the world.
This study was funded by grants from the Lustgarten Foundation and the Sky Foundation and National Cancer Institute grant No. R00CA263154 awarded to Steele. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
Coauthors of the study include Yuesong Wu, Daniel James Sålas-Escabillas, Aoqi Xie, Ian M. Loveless, Yasmine Baca, Kailee Hartway, Rama Shankar, Samuel D. Zwernik, Logan Schneider, Ashley George, Madison George, Allison Wombwell, Julie M. Clark, David S. Kwon, Bin Chen, Benjamin H. Hinrichs, Ralph Francescone, Débora Barbosa Vendramini-Costa, Kerem Ozcan, Zhengfan Xu, Ling Huang, Brian K. Theisen, Yuehua Cui and Howard C. Crawford.
Featured photo at top of pancreatic cancer cell courtesy of the National Cancer Institute/Unsplash.
Related Stories
Cancer Center experts present at national conference
May 27, 2025
University of Cincinnati Cancer Center researchers will present abstracts at the American Society of Clinical Oncology Annual Meeting May 30 to June 3 in Chicago.
Researchers work to make blood cancer a manageable disease
September 17, 2025
During Blood Cancer Awareness Month, Spectrum News and MSN highlighted researchers in the University of Cincinnati Cancer Center’s Leukemia and Drug Development Lab working to make blood cancer a manageable illness and bring new treatments to patients more efficiently than ever before.
Cancer Center plays key role in lab research, clinical trials for new pancreatic cancer drug
September 1, 2026
WLWT and WCPO highlighted the contributions of University of Cincinnati Cancer Center researchers that helped lead to the recent FDA approval of daraxonrasib, a new treatment for pancreatic cancer.